Premium
P1‐072: Comparison of measurements of medial temporal lobe atrophy in the prediction of Alzheimer's Disease in subjects with MCI
Author(s) -
Clerx Lies,
Pol Laura,
Rueckert Daniel,
Jong Remco,
Schijndel Ronald,
Verhey Frans R.J.,
Barkhof Frederik,
Wolz Robin,
Scheltens Philip,
Knol Dirk,
Lapuerta Pablo,
Visser Pieter Jelle,
Rossum Ineke,
Burns Leah
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.352
Subject(s) - medicine , clinical dementia rating , dementia , atrophy , nuclear medicine , receiver operating characteristic , temporal lobe , disease , epilepsy , psychiatry
molecules. The interaction of both labelled donor and acceptor molecules induced a fluorescence at 665nm proportional to the sAPP alpha level. A recombinant protein was used as standard. We investigated the CSF from 30 patients with AD, and 30 controls. CSFs were considered as AD profile according to tau protein, phosphorylated tau and As 1-42 results, as previously described (1). Excluded patients on the basis of CSF markers levels were considered as controls. Results: The test did not recognize recombinant sAPPs protein and As1-42 peptide. Sample dilutions (1/5, 1/10, 1/20) allowed to verify the response linearity. The test detected 3 ng/ml of sAPP alpha. 5 ml of sample was sufficient for the CSF quantification. Using this test, we could observed a significant increase of sAPP alpha in the CSF of 30 AD patients comparatively to 30 controls (AD:530 6 36 ng/ml; controls: 3936 28 ng/ml; p< 0.01). Interestingly, sAPP alpha was significantly correlated with As levels in control CSFs only (r2 :0.31; p< 0.001). No significant correlations were observed between tau or phosphorylated tau and sAPP alpha levels in CSF. Conclusions:We developed a very sensitive test for the quantification of sAPP alpha levels in human CSF. Using this test, we observed an increase of sAPP alpha level in the CSF of AD patients in absence of correlation with other markers contrary to that observed in controls. It will be interesting to investigate a larger population of AD and Mild Cognitive Impairment patients to study the putative correlations of sAPP alpha levels with the biomarkers and parameters of the disease. 1: DumurgierJ et al, (2010) NeurobiolDis. 40: 456-459